



# Proteomics International

LABORATORIES LTD

ASX Release

11 November 2022

ASX code: PIQ

## PromarkerD patent granted in Hong Kong

- **Proteomics International secures patent for PromarkerD predictive test for diabetic kidney disease in Hong Kong**
- **With an incidence rate of 11.6% of the total population, Hong Kong is home to 686,000 adults with diabetes**
- **Patent joins those already granted for the USA, Europe, Australia, Brazil, Canada, China, Indonesia, Russia, Singapore, India and Japan**
- **PromarkerD Intellectual property portfolio now covers 64% of the global population living with diabetes**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) announces it has secured a patent in Hong Kong for PromarkerD, the world's first predictive diagnostic test for diabetic kidney disease.

The prevalence of diabetes is increasing worldwide, particularly in Asian countries, which contribute 55% of the global population living with diabetes. Hong Kong is home to approximately 686,000 adults with diabetes<sup>1</sup>.

Proteomics International Managing Director Dr Richard Lipscombe said it was important to secure a patent for Hong Kong, which complements the Company's patent protection for the region. *"Proteomics International already has patent protection in China and the granting of the Hong Kong patent, which includes pre-diabetes expands that protection. Hong Kong is an important gateway market and there is the potential for PromarkerD testing to be introduced there prior to entering the much larger China market."*

The Hong Kong patent complements those already granted in the USA, Europe, Australia, Brazil, Canada, China, Indonesia, Russia, Singapore, India and Japan. Together, the Company's PromarkerD intellectual property portfolio covers 64% of the world's population living with diabetes.

The International Diabetes Federation estimates there are 537 million adults living with diabetes globally, and one-in-three currently have diabetic kidney disease<sup>2</sup>.

Dr Lipscombe said early detection of a decline in kidney function allows doctors and patients to take preventative action. *"PromarkerD can help prevent the need for renal replacement therapies such as dialysis and kidney transplant, potentially saving global healthcare systems billions of dollars a year."*

The Hong Kong patent (No. 1256827B) is titled 'Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions' and is valid until September 2031.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

<sup>1</sup> International Diabetes Federation Diabetes Atlas 10<sup>th</sup> edition, 2021

<sup>2</sup> Centers for Disease Control and Prevention. *Chronic Kidney Disease in the United States, 2019*

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

ENDS

**About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)